Literature DB >> 1982902

Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.

C A Tamminga1, J M Dale, L Goodman, H Kaneda, N Kaneda.   

Abstract

Vacuous chewing movements (VCMs) in three different rat strains developed at considerably different rates after 19 weeks of continual haloperidol treatment at an average daily dose of 1.5 mg/kg. Sprague Dawley (SD) rats displayed relatively high rates of VCMs with low variability, compared to Wistar (W) and Long Evan (LE) rats. Atropine decreased but did not abolish VCMs in two of the three strains (LE greater than SD). After haloperidol withdrawal, VCMs remitted gradually in all strains, but least rapidly in the SD rats. In a separate group of SD rats. VCMs were rated weekly from the start of haloperidol treatment and showed considerable interindividual variability. Even after 24 weeks of continuous haloperidol, 12 out of 32 treated rats showed no VCMs at all, while 13 out of 32 had intense movements, analogous to the clinical situation in which only some patients treated with neuroleptics develop tardive dyskinesia. These results indicate that there are individual and strain differences in the development of VCMs, and suggest that there may also be genetically determined differences in the development of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982902     DOI: 10.1007/bf02247127

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree.

Authors:  J L Waddington; H A Youssef
Journal:  Br J Psychiatry       Date:  1988-09       Impact factor: 9.319

2.  Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.

Authors:  D Tarsy; R J Baldessarini
Journal:  Neuropharmacology       Date:  1974-11       Impact factor: 5.250

3.  An experimental model of tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

4.  Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.

Authors:  A Clow; A Theodorou; P Jenner; C D Marsden
Journal:  Adv Biochem Psychopharmacol       Date:  1980

5.  Oral dyskinesia in rats following brain lesions and neuroleptic drug administration.

Authors:  L M Gunne; J Growdon; B Glaeser
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.

Authors:  G Gardos; J O Cole; R M Rapkin; R A LaBrie; E Baquelod; P Moore; R Sovner; J Doyle
Journal:  Arch Gen Psychiatry       Date:  1984-11

7.  Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.

Authors:  N M Rupniak; S Mann; M D Hall; S Fleminger; G Kilpatrick; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.

Authors:  J L Waddington; A J Cross; S J Gamble; R C Bourne
Journal:  Science       Date:  1983-04-29       Impact factor: 47.728

9.  Relationship of serum haloperidol levels to clinical response in schizophrenic patients.

Authors:  J R Magliozzi; L E Hollister; K V Arnold; G M Earle
Journal:  Am J Psychiatry       Date:  1981-03       Impact factor: 18.112

10.  Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.

Authors:  R C Smith; R Baumgartner; C H Misra; M Mauldin; A Shvartsburd; B T Ho; C DeJohn
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more
  15 in total

1.  Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.

Authors:  G E Meredith; I E De Souza; T M Hyde; G Tipper; M L Wong; M F Egan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.

Authors:  Ian E J De Souza; Niamh M Dawson; Jeremiah J Clifford; John L Waddington; Gloria E Meredith
Journal:  Psychopharmacology (Berl)       Date:  2003-06-27       Impact factor: 4.530

3.  Drug-induced oral dyskinesias in rats after traditional and new neuroleptics.

Authors:  T Kakigi; X M Gao; C A Tamminga
Journal:  J Neural Transm Gen Sect       Date:  1995

4.  Spontaneous orofacial movements in rodents induced by long-term neuroleptic administration: a second opinion.

Authors:  G Ellison
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Authors:  Emma Perez-Costas; Paolo Guidetti; Miguel Melendez-Ferro; Joyce J Kelley; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

6.  Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.

Authors:  B Glenthøj
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

8.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.

Authors:  X M Gao; T Kakigi; M B Friedman; C A Tamminga
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia.

Authors:  Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Young-Min Park; Se-Won Lim; Min Kyu Rhee; Seung-Hyun Kim; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.